The CHRNA9 antibody targets the alpha-9 subunit of the nicotinic acetylcholine receptor (nAChR), encoded by the *CHRNA9* gene. This subunit forms ligand-gated ion channels, primarily in non-neuronal tissues, and plays a critical role in auditory function, inflammation modulation, and cellular signaling. CHRNA9 is notably expressed in the cochlea, where it contributes to hair cell development and sound transduction. Dysregulation of CHRNA9 is linked to hearing disorders, including age-related and noise-induced hearing loss.
Beyond auditory pathways, CHRNA9 is involved in immune regulation, influencing cytokine release and immune cell activity. Its aberrant expression has been observed in cancers (e.g., breast, lung) and autoimmune diseases, suggesting roles in tumor progression and inflammation. CHRNA9 antibodies are essential tools for studying receptor localization, expression patterns, and functional interactions in both physiological and pathological contexts.
Researchers use these antibodies in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore CHRNA9's role in cellular signaling, disease mechanisms, and therapeutic targeting. Recent studies also investigate CHRNA9's potential as a biomarker or drug target for hearing disorders and cancer immunotherapy. Despite its niche focus, CHRNA9 research highlights the receptor's diverse impact across sensory, immune, and oncological systems.